
Biogen has linked its tau-targeting antisense oligonucleotide to a further slowing of clinical decline after two years, leading analysts to hail the strengthening of evidence supporting late-phase development.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks

